A retrospective comparison of mitoxantrone-melphalan and BEAM conditioning regimens before autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma patients

dc.authoridAysun Halaçoğlu / 0000-0001-6055-6404en_US
dc.authoridSongül Şerefhanoğlu / 0000-0002-0256-9714
dc.authorscopusidAysun Halaçoğlu / 55331935800
dc.authorscopusidSongül Şerefhanoğlu / 22955014900
dc.authorwosidAysun Halaçoğlu / HZJ-4538-2023
dc.authorwosidSongül Şerefhanoğlu / FWQ-9992-2022
dc.contributor.authorHalaçoğlu, Aysun
dc.contributor.authorŞerefhanoğlu, Songül
dc.date.accessioned2021-05-18T09:55:04Z
dc.date.available2021-05-18T09:55:04Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAbstract High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) is considered the standard therapy for patients with relapsed lymphoma. The aim of our study is the comparison of mitoxantrone-melphalan and BEAM (carmustine, etoposide, cytarabin and melphalan) conditioning regimens before autologous hematopoietic stem cell transplant in patients with lymphoma. This study has been performed in a retrospective manner. Hundred and two patients with relapsed/refractory Hodgkin lymphoma (n = 35) and non-Hodgkin lymphoma (n = 67) who underwent high-dose treatment followed by AHSCT at Memorial Sisli Hospital between 2013 and 2018 were evaluated. We retrieved data on patient demographics, disease status and post AHSCT outcomes. For conditioning regimen 52 patients received mitoxantrone (60 mg/m(2) x 1 day) and melphalan (180 mg/m(2) x 1 day) and 50 patients received BEAM (carmustine at 300 mg/m(2) x 1 day, etoposide at 200 mg/m(2) x 4 days, cytarabine at 2 x 200 mg/m(2) x 4 days and melphalan at 140 mg/m(2) x 1 day). The median age was 45 (18-73) years at the time of the diagnosis. No significant difference was observed in baseline characteristics between groups, including the disease control and previous therapies. Prior to high-dose chemotherapy, 79.4% of the patients were in complete remission (CR) and 20.6% was in partial remission (PR). With a median follow up of 30.5 months (range: 1-70 months) for the whole cohort, even though the OS was similar in both groups (86% +/- 2.4 vs. 84% +/- 3.2; p = 0.85), the PFS was noted to be superior among those who received conditioning with BEAM protocol (55% +/- 3.7) compared to those with mitoxantrone-melphalan (30.6% +/- 2.8; p = 0.006). In conclusion, we demonstrated that the BEAM regimen is an effective high-dose chemotherapy for lymphoma patients before AHSCT. Nevertheless mitoxantrone-melphalan regimen is also an alternative to the BEAM regimen.en_US
dc.identifier.citationHalacoglu, A., & Serefhanoglu, S. (2021). A Retrospective Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphoma Patients. Indian Journal of Hematology and Blood Transfusion, 1-7.en_US
dc.identifier.doi10.1007/s12288-021-01439-4en_US
dc.identifier.issn0971-4502en_US
dc.identifier.issn0974-0449en_US
dc.identifier.scopus2-s2.0-85105245100en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://www.doi.org/10.1007/s12288-021-01439-4
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1740
dc.identifier.wosWOS:000647521700002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorHalaçoğlu, Aysun
dc.institutionauthorŞerefhanoğlu, Songül
dc.language.isoenen_US
dc.publisherSPRINGER INDIAen_US
dc.relation.ispartofINDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLymphomaen_US
dc.subjectConditioning Regimenen_US
dc.subjectAutologous Stem Cell Transplantationen_US
dc.titleA retrospective comparison of mitoxantrone-melphalan and BEAM conditioning regimens before autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
24.pdf
Boyut:
551.28 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: